The phase III AMEERA-5 trial (NCT04478266) was designed to determine whether the addition of amcenestrant to palbociclib would improve PFS vs letrozole plus palbociclib in patients with ER + , HER2 − advanced breast cancer who have not previously received systemic therapy. This evidence concerns the gene ESR1 and breast cancer.